Green Cross US FDA OK to test new anti-Parkinsonian drug candidate

Green Cross Corporation said on February 10 it has received approval from the U.S. Food and Drug Administration to start an early-stage human trial of GCC1290K for the treatment of Parkinson’s disease.

The company said GCC1290K is a novel neuroprotectant to treat Parkinson’s disease. After oral or intravenous administration, GCC1290K is rapidly converted to a parent drug, 3-Hydroxymorphinan ...